We Devoted Ourselves To The Development Of Biomedical Research Reagent.
Product Details
Ruxolitinib,941678-49-5,IC-0223583
Ruxolitinib (INCB018424), as an inhibitor, inhibits Janus-associated kinases (JAKs)JAK1 and JAK2 with IC50 values of 3.3 nM and 2.8 nM, respectively. Ruxolitinib mediates several cytokine and growth factor signaling important for hematopoietic and immune function[1-3].
Ruxolitinib (INCB018424) (500nM-50μM;30min) significantly inhibited the production of IL-6, TNF-α and MCP-1 as induced by A23817 and substance P in HMC1 cells[4]. Ruxolitinib(0-400nM; 3days) reduced the level of cytokine release in CAR-T cells[5].
Ruxolitinib (INCB018424) (30 mg/kg; p.o.; twice a day 14 days) treatment alleviated renal damage in UUO mice[6]. Ruxolitinib(twice daily by oral gavage; 2 weeks) treatment improves viability and splenomegaly in a JAK2V617F-driven model of malignant disease[3]. Treatment of Fancc-/- mice with ruxolitinib(45 mg/kg; i.p; 5 days/week) decreased anemia, enhanced granulocytosis, delayed clonal progression and prolonged survival during repeated emergency granulopoiesis episodes[7].
Ruxolitinib (INCB018424), as an inhibitor, inhibits Janus-associated kinases (JAKs)JAK1 and JAK2 with IC50 values of 3.3 nM and 2.8 nM, respectively. Ruxolitinib mediates several cytokine and growth factor signaling important for hematopoietic and immune function[1-3].
Ruxolitinib (INCB018424) (500nM-50μM;30min) significantly inhibited the production of IL-6, TNF-α and MCP-1 as induced by A23817 and substance P in HMC1 cells[4]. Ruxolitinib(0-400nM; 3days) reduced the level of cytokine release in CAR-T cells[5].
Ruxolitinib (INCB018424) (30 mg/kg; p.o.; twice a day 14 days) treatment alleviated renal damage in UUO mice[6]. Ruxolitinib(twice daily by oral gavage; 2 weeks) treatment improves viability and splenomegaly in a JAK2V617F-driven model of malignant disease[3]. Treatment of Fancc-/- mice with ruxolitinib(45 mg/kg; i.p; 5 days/week) decreased anemia, enhanced granulocytosis, delayed clonal progression and prolonged survival during repeated emergency granulopoiesis episodes[7].
